Thyroid Cancer: Drugs

Department of Health written question – answered at on 25 July 2016.

Alert me about debates like this

Photo of Lord Freyberg Lord Freyberg Crossbench

To ask Her Majesty’s Government whether they plan to consider providing interim funding for innovative treatments for patients with radioactive-iodine refractory differentiated thyroid cancer where there are treatments available but they are yet to be reviewed by NICE.

Photo of Lord Prior of Brampton Lord Prior of Brampton The Parliamentary Under-Secretary of State, Department of Health

The Cancer Drugs Fund (CDF) already provides access to sorafenib as a treatment option for the systemic therapy of locally advanced or metastatic differentiated radioiodine-refractory thyroid cancer.

The National Institute for Health and Care Excellence (NICE) has been asked to develop technology appraisal guidance on the use of sorafenib and lenvatinib for this indication.

NHS England published its new standard operating procedure for the CDF in July 2016 and a copy is attached.

NHS England has advised that it considered carefully the issue as to which drugs should be given interim funding and concluded, with the support of the majority of stakeholders, that interim funding should only be possible for those drugs that had been granted a marketing authorisation and were in receipt of a draft positive appraisal recommendation or a draft recommendation for use within the CDF from NICE.

CDF SOP (PDF Document, 380.63 KB)

Does this answer the above question?

Yes1 person thinks so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.